Post by
Bully88 on Apr 13, 2021 7:50am
Valuable Information
Below I will be posting valuable information and comments directly taken out of the MD&A posted on Sedar, for you all to review
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
COMMERCIAL ACTIVITIES
The Company has a national, clinical reference laboratory specializing in personalized blood-based tests to find, understand and treat cancers, which operates from a single facility in Richmond, Virginia, that is capable of servicing the entire United States, Canada and Europe.
The Company is working to secure multi-year agreements with hospitals, integrated clinical networks, large physician groups and healthcare organizations for StageZero Life Sciences’ risk assessment tests to assist in the early detection of cancer. This is in addition to work being done with high-risk populations, their employers and in the telemedicine arena.
The focus is on Four Primary Growth Areas:
Small Independent Medical Practices:
Ranging in size from 1 to 10 providers, with reimbursement for the tests via billing to insurers and patient-pay, is an important sector of the market. We are steadily increasing the number of practices using our tests, especially on a routine, weekly basis and have significantly restructured and upgraded our billing procedures. We expect this segment to contribute about 10-15% of our test volume.
High-Risk Populations/self-funded employer plans:
Early detection of cancer as well as risk stratification into normal, high and “raised” risk is of critical importance in workers exposed to carcinogens. The Company is working with multiple high-risk employer partners across the country and has initiated screening within these high-risk groups. We are also in discussion with several self-funded employer plans and have significant interest in our programs. Reimbursement to the Company is direct and either immediate, or within 45 days upon invoice.
TeleMedicine/Patient Directed Testing:
The global telehealth market was valued at US$50 billion in 2018 and some predict it to reach US$267 billion by 2026.1 Currently, 74% of employers in the United States now offer telemedicine as a covered benefit.2 Similarly, Americans age 45-54 and 65+ are most likely to delay needed care due to wait times.3 On average, it takes approximately twenty-one (21) days for a new patient to see a primary care provider4 and 66% of consumers are willing to use telehealth to get faster service and costs savings.5 According to the National Business Group on Health Plan Design Survey, large employers offering telemedicine is increasing.
Large Healthcare Systems:
Are one of our largest opportunities and we are in discussion with several large systems. The company is working on implementation of our programs into these systems. Implementation is complex as there are many stakeholders within a large system and all have to be coordinated. Contracts will be executed and announced once implementation is fully in place. Payment to the Company is by invoice and within 45 days.
MyCancerRisk:
The Company’s MyCancerRisk Data Analytics™ Platform is being developed to track and analyze aggregate cancer screening data in order to monitor performance on testing and early intervention. This platform is expected to bring significant value to large healthcare systems and self-insured organizations who want to monitor compliance with cancer screening, risk stratify their patient populations, and improve early intervention.
OUTLOOK
At the heart of the Company’s mission to improve health outcomes is our ability to provide physicians and their patients with actionable clinical data for cancer risk assessment and diagnosis. ColonSentry, as the first blood-based, early colorectal cancer diagnostic test to be developed from the Sentinel Principle platform has been validated in both a 10,000 patient prospective study and a 100,000 patient post-marketing study, which confirmed the strength of the science. Aristotle, our next-generation diagnostic test, can test for ten cancers from a single sample of blood, with data to date indicating high sensitivity and specificity across the individual cancers. The Sentinel Principle platform is therefore proven, not promised. It is anticipated that full clinical validation will be completed within two years.
Access to patient friendly, blood-based tests that can detect disease at its earliest stages is truly innovative, especially when multiple disease states can be screened for from a single sample of blood. Aristotle does that, in this case, for multiple cancers and will allow early diagnosis at the population health level. This has implications for self-funded employer plans which have employees in high-risk environments (Fire fighters, oil and gas, coal and chemical plants, pilots and flight attendants, drivers), large healthcare systems, especially those with outreach programs and benefit plans, the military, as well as individual States which have specific populations that need to be screened.
As a prelude to this in 2018, StageZero Life Sciences began the process of collecting and sharing aggregated data in an effort to build a data-driven product to help practices and healthcare systems better understand their patient populations and build more effective programs to improve patient compliance with cancer screening, preventive health programs, and early interventions. During 2019 we expanded this effort as we initiated research programs with key high-risk groups and focused on supporting these programs into the roll-out of our four distinct commercial paths. We expect data as an asset to continue to be a key strategy for us.
In 2020 and early 2021, we have:
• Aggressively expanded the programs under MyCancerRisk™ to High Risk Patient Populations and their employers. Pilot program data shows 34% of those tested had a raised risk result for cancer.
• Initiated the Patient Directed Testing program with 8,000+ draw sites and TeleHealth Physician Networks.
• Initiated test implementation planning with Large HealthCare Systems. This runs parallel with contract completion. Management’s objective is to have test introduction logistics completed concurrent with signature of agreements.
• Consolidated planning with large employers of high-risk employees to initiate extensive screening programs.
• Continued to expand the Small Clinical Practice base and upgraded Billing and revenue collection systems.
• Initiated full clinical validation of Aristotle.
We continue to develop four distinct revenue streams:
• High Risk Patients - payment collected immediately
• Telemedicine - payment collected immediately or invoiced to Networks with payment within 45 days
• Large HealthCare Systems - fixed price per test, invoiced and paid within 45 days
• Small Clinical Practices - standard billing to insurers/CMS. Process being significantly upgraded.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
This is very valuable information for you to base your judgement of this companies current fundamental business.
Things are looking very strong for them. (Besides the way we chose to release our sheit lol)
We have all the pieces in place now for this platform to grow massive.
Congrats to everyone who buys at these measily low prices. In a year from now you will be kicking yourself for not buying more. IMO
I practice what I preach. I had recently stated that I sold at around $1.05 to get my money out plus an ROI of 15%. I have since then done alot of reading and research to be comfortable with buying back in with what i took off, buying at .72. Thus bringing my holdings of this company to 1/3rd more then what i had originally owned.
Every Quarter from this point forward should produce gains in revenue growth in all of the above points. Bringing our share price up with it.
I now see this as a growth stock that will continuously build its cash and assets while keeping their already extremely low debt and outstanding shares very small.
"I like the stock"
Cheers,
Bully